Janux Therapeutics Inc (JANX)
47.71
-0.20
(-0.42%)
USD |
NASDAQ |
May 15, 15:12
Janux Therapeutics Revenue (Quarterly): 1.252M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 1.252M |
| December 31, 2023 | 2.461M |
| September 30, 2023 | 2.517M |
| June 30, 2023 | 1.057M |
| March 31, 2023 | 2.048M |
| December 31, 2022 | 2.845M |
| September 30, 2022 | 1.813M |
| Date | Value |
|---|---|
| June 30, 2022 | 2.365M |
| March 31, 2022 | 1.589M |
| December 31, 2021 | 1.616M |
| September 30, 2021 | 1.159M |
| June 30, 2021 | 0.482M |
| March 31, 2021 | 0.38M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.38M
Minimum
Mar 2021
2.845M
Maximum
Dec 2022
1.660M
Average
1.616M
Median
Dec 2021
Revenue (Quarterly) Benchmarks
| Viking Therapeutics Inc | -- |
| Equillium Inc | 10.69M |
| Minerva Neurosciences Inc | -- |
| Arvinas Inc | 25.30M |
| Calidi Biotherapeutics Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -14.76M |
| Total Expenses (Quarterly) | 21.41M |
| EPS Diluted (Quarterly) | -0.30 |
| Enterprise Value | 1.832B |
| Profit Margin (Quarterly) | -1.18K% |
| Earnings Yield | -2.54% |
| Normalized Earnings Yield | -2.536 |